Broadening covalent neoantigens to mobilize immune defense
A new platform shows that cysteine-reactive covalent modifications of intracellular proteins can be processed and presented as covalent neoantigens on MHC class I, and a bioorthogonal strategy enables immune-cell engagement by linking these neoantigens to recruiters that activate CD32- and CD3-expressing reporters, thereby expanding the repertoire of covalent neoantigens and offering a general approach to immune targeting of haptenated neoepitopes.